Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

ConclusionIn this interim analysis, adults with moderate to severe PsO had higher long-term response rates at 2 years when treated with deucravacitinib versus adalimumab. Deucravacitinib response rates remained stable whereas adalimumab response rates declined in year 2.Graphical Abstract

http://rd.springer.com/10.1007/s13555-023-00977-1

Source: Dermatology and Therapy - October 29, 2023 Category: Dermatology Source Type: research